8.02
-9.94%
Close of 20 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $334.7m
- Last close × shares
- Volume
- 1.4m
- Shares, 20 Nov 2026
About Senseonics Holdings
From its filings with the US Securities and Exchange Commission
Senseonics Holdings is based in Germantown, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SENS. The SEC classifies its business as industrial instruments for measurement, display, and control. In the fiscal year to 31 December 2025, it reported revenue of $35.3m and a net loss of $69.1m. At that date it held total assets of $126.3m and shareholders' equity of $61.0m.
We are a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (“CGM”) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Our implantable CGM system (“Eversense”), including Eversense E3 and Eversense 365 CGM systems are designed to continually and accurately measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to twelve months in the case of Eversense 365 and six months in the case of Eversense E3, as compared to seven to 15 days for non-implantable CGM systems. In September 2024, the 365-day extended life Eversense E3 CGM system was approved by the FDA and, through Ascensia Diabetes Care Holdings AG (“Ascensia”), we began commercializing Eversense 365 in the fourth quarter of 2024. In January 2026, we took over full commercial responsibility for Eversense 365 in the United States and began marketing and distributing the product with our own sales force. In June 2022, we affixed the CE Mark to the Eversense E3 CGM system and Ascensia began commercialization in select markets in Europe during the third quarter of 2022. In January 2026, the Company obtained CE Mark approval for Eversense 365 and expects to launch Eversense 365 in the European Territories by the second half of 2026.
Quoted from its 10-K, filed 2 Mar 2026. Read the filing on SEC.gov ↗
Latest on Senseonics Holdings
Our reporting
We have not reported on Senseonics Holdings yet.
Next results
Due on 1 Mar 2027. Analysts expect earnings of -0.41 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is Senseonics Holdings's ticker?
Senseonics Holdings trades as SENS on its US listing, under ISIN US81727U3032.
What was Senseonics Holdings's last closing price?
8.02 on 20 Nov 2026. The figure is in USD and is never converted.
When does Senseonics Holdings next report results?
Results are expected on 9 Nov 2026, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.